Related Experiment Video

Updated: Jun 25, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Optimal targeting of the mTORC1 kinase in human cancer

Heidi A Lane1, Madlaina Breuleux

  • 1Basilea Pharmaceutica International AG, Basel, Switzerland. heidi.lane@basilea.com

Current Opinion in Cell Biology
|February 24, 2009
PubMed

Insights

The mammalian target of rapamycin complex 1 (mTORC1) kinase is crucial in tumor biology. mTORC1 inhibitors show antitumor activity, with specific tumors responding due to PI3K/mTORC1 pathway deregulation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The mammalian target of rapamycin complex 1 (mTORC1) kinase is a central regulator of cell growth, metabolism, and survival.
  • mTORC1 signaling is frequently dysregulated in various cancers, making it a promising therapeutic target.

Purpose of the Study:

  • To review strategies for optimizing the clinical development of mTORC1 inhibitors.
  • To discuss challenges and opportunities in leveraging mTORC1 inhibition for cancer therapy.

Main Methods:

  • Review of preclinical and clinical data on mTORC1 inhibitors.
  • Analysis of signaling pathways involved in mTORC1 inhibition response and resistance.
  • Examination of clinical trial outcomes and patient stratification approaches.

Main Results:

  • mTORC1 inhibitors demonstrate broad preclinical and clinical antitumor activity.
  • Tumor-specific responses to mTORC1 inhibition are linked to PI3K/mTORC1 pathway deregulation.
  • mTORC1 inhibition can activate compensatory survival pathways, necessitating combination strategies.

Conclusions:

  • Optimizing mTORC1 inhibitor therapy requires understanding pathway crosstalk and compensatory mechanisms.
  • Rational target combinations, biologically based dosing, and patient stratification are key to maximizing clinical benefit.
  • Further research into predictive biomarkers and combination therapies is essential for advancing mTORC1-targeted cancer treatment.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...